SCHEDULE: Trails Edge Capital Reduces Milestone Pharma Stake Below 5%

Trails Edge Capital Partners, LP and affiliates have filed an amended Schedule 13G, disclosing their beneficial ownership in Milestone Pharmaceuticals Inc. has fallen to 4.3%.

Summary

• Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai (collectively, the "Filers") have filed an Amendment No. 2 to their Schedule 13G.
• As of March 20, 2026, the Filers beneficially own an aggregate of 5,333,333 common shares of Milestone Pharmaceuticals Inc.
• This ownership represents approximately 4.3% of the outstanding common shares of Milestone Pharmaceuticals Inc.
• The shares are derived from Series B warrants held directly by Trails Edge Biotechnology Master Fund, LP.
• The ownership percentage is based on 117,667,277 shares reported as issued and outstanding by Milestone Pharmaceuticals Inc. as of March 20, 2026.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure. It's a routine regulatory filing indicating a change in beneficial ownership below a key reporting threshold, without explicit positive or negative implications for the issuer's operations or prospects.

Future Outlook

This filing does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G/A provide transparency into significant holdings. A reduction in beneficial ownership below the 5% threshold, while not necessarily indicative of a negative outlook, means the reporting entity is no longer required to file subsequent amendments unless their stake again crosses a reporting threshold. This can sometimes reduce visibility into a significant investor's position.

Comparison to Industry Standards

• Institutional investors frequently adjust their positions in public companies. A 4.3% stake, while below the 5% reporting threshold for Schedule 13D/G, still represents a notable holding for an investment manager like Trails Edge Capital.
• For example, a similar stake in a small-cap biotech company like Milestone Pharmaceuticals Inc. could be considered a significant position, whereas in a large-cap pharmaceutical company, it would be a minor holding.
• Without specific prior holdings or market context, it is difficult to compare this specific stake to industry benchmarks, but generally, institutional investors often hold stakes ranging from 1% to 10% in their portfolio companies.

Stakeholder Impact

• Shareholders: The reduction in beneficial ownership below 5% by Trails Edge Capital Partners, LP and its affiliates means they are no longer required to file ongoing updates unless their stake crosses a reporting threshold again. This could slightly reduce transparency for other shareholders regarding this specific institutional investor's position.

Key Dates

Recommendation

This filing is a routine regulatory disclosure of a passive investment stake falling below the 5% threshold. It does not provide information about the company's financial performance, strategic direction, or operational health that would warrant a "buy" or "sell" recommendation. Investors should "hold" and look to the company's financial reports and other disclosures for investment decisions.

Keywords

Milestone Pharmaceuticals Inc., Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, Ortav Yehudai, Schedule 13G/A, beneficial ownership, common shares, institutional ownership, equity stake, investment manager, warrants